Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
287.16
+12.40 (4.51%)
At close: Aug 13, 2025, 4:00 PM
287.16
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:30 AM EDT
Bio-Rad Laboratories Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Bio-Rad Laboratories stock ranges from a low of $265 to a high of $409. The average analyst price target of $333.5 forecasts a 16.14% increase in the stock price over the next year.
Price Target: $333.50 (+16.14%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Bio-Rad Laboratories stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $387 → $409 | Buy | Maintains | $387 → $409 | +42.43% | Aug 1, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $245 → $265 | Hold | Maintains | $245 → $265 | -7.72% | Aug 1, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $260 → $245 | Hold | Maintains | $260 → $245 | -14.68% | Jun 9, 2025 |
| UBS | UBS | Strong Buy Maintains $355 → $310 | Strong Buy | Maintains | $355 → $310 | +7.95% | May 2, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $400 → $350 | Strong Buy | Maintains | $400 → $350 | +21.88% | May 2, 2025 |
Financial Forecast
Revenue This Year
2.55B
from 2.57B
Decreased by -0.76%
Revenue Next Year
2.63B
from 2.55B
Increased by 3.42%
EPS This Year
8.52
from -65.36
EPS Next Year
9.37
from 8.52
Increased by 9.95%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.7B | 2.8B | 2.9B | ||
| Avg | 2.5B | 2.6B | 2.7B | ||
| Low | 2.4B | 2.5B | 2.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.1% | 9.1% | 11.4% | ||
| Avg | -0.8% | 3.4% | 4.2% | ||
| Low | -4.7% | -1.8% | -1.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.69 | 10.83 | 13.34 | ||
| Avg | 8.52 | 9.37 | 10.78 | ||
| Low | 7.33 | 7.30 | 7.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 27.0% | 42.3% | ||
| Avg | - | 9.9% | 15.1% | ||
| Low | - | -14.3% | -17.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.